Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $80

Futu NewsMar 18 01:31 · Ratings

Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $80

BenzingaMar 18 00:44 · Ratings

Express News | Legend Biotech Corp : Morgan Stanley Cuts Target Price to $80.00 From $82.00

BreakingsMar 17 22:10

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and EyePoint Pharmaceuticals (EYPT)

TipRanksMar 17 17:50 · Ratings

Morgan Stanley: Reiterates GENSCRIPT BIO "Shareholding" rating and raises the Target Price to HKD 21.9.

Morgan Stanley released a research report reaffirming the "Shareholding" rating for GENSCRIPT BIO (01548), raising the Target Price from HKD 18.6 to HKD 21.9. The bank stated that last year, GENSCRIPT BIO's non-cell therapy business performance largely met expectations, with management setting a target for all core Business Sectors to achieve accelerated double-digit growth by 2025. After no longer consolidating Legend Biotech's financial statements, a profit of approximately USD 2.9 billion has been recorded for the year. GENSCRIPT has achieved profitability from an accounting standpoint. Morgan Stanley stated that the recovery trend for GENSCRIPT is expected to continue into 2025, making the operational outlook more optimistic, and believes it will be positively impacted by Global.

Sina Hong Kong Stock.Mar 17 14:27

Genscript Biotech Releases Supplemental Announcement on Legend Biotech's Financial Results

TipRanksMar 14 18:41